AutoContour v2.7
Unified AI-driven contouring platform for radiation therapy
Software · On PremiseCompany source
Company profile
About Limbus AI
Limbus AI is a leading global provider of automated contouring software for radiation therapy, acquired by Radformation in April 2024. The company's flagship product, AutoContour v2.7 (formerly Limbus Contour), delivers fast, consistent, and scalable AI-driven contouring across multiple imaging modalities including CT, MR, and CBCT. The platform generates high-quality contours of organs at risk (OARs) and clinical target volumes (CTVs) in 1-3 minutes using deep learning models that run entirely on local clinical workstations, eliminating cloud data transfer and privacy concerns. With an extensive library of 260+ clinically validated anatomical structures covering head & neck, thorax & abdomen, pelvis, CNS, and gynecological sites, Limbus Contour integrates seamlessly with existing treatment planning systems through DICOM RT-Structure export. The solution has processed over 100,000 scans worldwide and delivers contours 5-10x faster than manual methods. The platform features zero-click automation that detects treatment sites and applies appropriate clinical templates, or integrates directly into treatment planning systems for streamlined workflows. Limbus AI serves radiation oncology departments in health systems globally, focusing on reducing contouring variability, accelerating treatment planning, and improving clinical efficiency while maintaining expert-grade quality backed by comprehensive clinical research.
Company description Limbus AI official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Limbus AI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Abdominal Cancer
- Breast Cancer
- CNS/Brain Cancer
- Gynecological Cancer
- Head & Neck Cancer
- Pelvic Cancer
- Prostate Cancer
- Thoracic Cancer
Who it serves
- Cancer Centers
- Health Systems
- Radiation Oncology Departments
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: Treatment Planning Systems (TPS) via DICOM RT-Structure export, Vendor neutral - supports wide variety of TPS platforms.
Geographic context
MarketsGlobal
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by Radformation Inc. on April 30, 2024. Launch of AutoContour v2.7 unifying AutoContour and Limbus Contour into one platform.
Partnerships
Recorded partners
- Radformation (acquired by, April 2024)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Limbus Contour
Automatic contouring for radiation therapy with clinical grade contours
Software · On PremiseCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Inverse treatment planning using deep learning-based organs at risk in radiotherapy for head and neck cancer: a prospective planning study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · Mar 30, 2026
Implementation of deep learning-based auto-segmentation for radiotherapy planning structures: a workflow study at two cancer centers.Radiation oncology (London, England) · Jun 8, 2021
Training and Validation of Deep Learning-Based Auto-Segmentation Models for Lung Stereotactic Ablative Radiotherapy Using Retrospective Radiotherapy Planning Contours.Frontiers in oncology · Jan 1, 2021
Comparing deep learning-based auto-segmentation of organs at risk and clinical target volumes to expert inter-observer variability in radiotherapy planning.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · Mar 1, 2020
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
Limbus ContourK241837 · 510k · Oct 9, 2024
Limbus ContourK230575 · 510k · Apr 7, 2023
Limbus ContourK201232 · 510k · Aug 13, 2020
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
5-10x faster than manual contouring
Contouring speed improvement
Under 3 minutes average contouring time
Local CPU installations
1 minute average contouring time
Local GPU installations
100,000+ scans contoured
Clinics worldwide
Clinics worldwide
Automated contouring for radiation therapy across multiple sites
Over 100,000 scans contoured with average time under 3 minutes on CPU, 1 minute on GPU. 5-10x faster than manual contouring
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Limbus AI
Recent articles published on Limbus AI's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.